Back to Principal


Latest news

Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors

Maxion Therapeutics Expands Team and Facilities with Move to Unity Campus

Maxion Therapeutics Wins ‘Start-up of the Year’ at 2023 Cambridge Independent Science & Technology Awards

Maxion Therapeutics Awarded £2 million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-to-Treat" Autoimmune Diseases

Maxion Therapeutics’ $16 million Series A to drive antibody development for previously untreatable ion channel and GPCR-driven diseases

Maxion Therapeutics strengthens its Board with the appointment of Ian Tomlinson (Chairman), Tom Weaver (Non-Executive Director), and Aneesh Karatt Vellatt (Director)